{"id":"endotag-1-and-gemcitabine","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"EndoTAG-1 selectively binds to the tumor vasculature, causing damage to the endothelial cells and disrupting tumor blood supply. Gemcitabine, on the other hand, is a prodrug that is converted into its active form, which is then incorporated into DNA, causing DNA strand breaks and inhibiting DNA synthesis, leading to cell death.","oneSentence":"EndoTAG-1 is a peptide that targets the tumor vasculature, while Gemcitabine is a nucleoside analog that interferes with DNA synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:50:57.086Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT03126435","phase":"PHASE3","title":"EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX","status":"COMPLETED","sponsor":"SynCore Biotechnology Co., Ltd.","startDate":"2018-10-16","conditions":"Metastatic Pancreas Cancer, Locally Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma","enrollment":218},{"nctId":"NCT03002103","phase":"PHASE3","title":"A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer","status":"SUSPENDED","sponsor":"SynCore Biotechnology Co., Ltd.","startDate":"2016-11-23","conditions":"Triple-Negative Breast Cancer","enrollment":420},{"nctId":"NCT00377936","phase":"PHASE2","title":"EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas","status":"COMPLETED","sponsor":"MediGene","startDate":"2005-09","conditions":"Adenocarcinoma, Metastasis, Pancreas Neoplasms","enrollment":212}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"EndoTAG-1 and Gemcitabine","genericName":"EndoTAG-1 and Gemcitabine","companyName":"MediGene","companyId":"medigene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EndoTAG-1 is a peptide that targets the tumor vasculature, while Gemcitabine is a nucleoside analog that interferes with DNA synthesis. Used for Pancreatic cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}